12:09:15 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2020-11-10 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-05-13 Kvartalsrapport 2020-Q1
2020-04-29 Årsstämma 2020
2020-03-31 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-08 Kvartalsrapport 2019-Q2
2019-05-06 Kvartalsrapport 2019-Q1
2019-04-04 Ordinarie utdelning VELO 0.00 DKK
2019-04-03 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-13 Kvartalsrapport 2018-Q2
2018-05-14 Kvartalsrapport 2018-Q1
2018-04-16 Ordinarie utdelning VELO 0.00 DKK
2018-04-13 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-14 Kvartalsrapport 2017-Q3
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Kvartalsrapport 2017-Q1
2017-04-10 Ordinarie utdelning VELO 0.00 DKK
2017-04-07 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-07-26 Extra Bolagsstämma 2016
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-07 Ordinarie utdelning VELO 0.00 DKK
2016-04-06 Årsstämma 2016
2016-03-09 Bokslutskommuniké 2015
2015-11-11 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-20 Kvartalsrapport 2015-Q1
2015-03-27 Ordinarie utdelning VELO 0.00 DKK
2015-03-26 Årsstämma 2015
2015-03-03 Bokslutskommuniké 2014
2014-04-10 Ordinarie utdelning VELO 0.00 DKK
2013-04-18 Ordinarie utdelning VELO 0.00 DKK
2013-04-17 Årsstämma 2013
2012-04-19 Ordinarie utdelning VELO 0.00 DKK
2011-04-13 Ordinarie utdelning
2010-04-22 Ordinarie utdelning

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Veloxis Pharmaceuticals är ett läkemedelsbolag. Särskild specialisering återfinns inom behandlingen av organavstötning vid organtransplantationer. Visionen är att erbjuda läkemedel som underlättar absorptionen av läkemedel som fås oralt vid ingreppet. Bolaget innehar verksamhet på global nivå, främst inom Europa och Nordamerika. Veloxis Pharmaceuticals grundades 2002 och har sitt huvudkontor i Köpenhamn.
2018-08-31 06:27:00

Company Release no. 16/2018

To: NASDAQ Copenhagen A/S                                                

Copenhagen, Denmark, 31 August 2018


Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of
31 August 2018


Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of the Danish Statutory Order on Issuers’ Disclosure Obligations, the total number of shares and voting rights in the Company at the end of a calendar month in which changes to the share capital have occurred.

With reference to Company Release no. 15/2018 dated 23 August 2018 informing of an increase in the share capital and the voting rights after exercise of employee warrants, the table below provides the total number of shares and voting rights in Veloxis as of 31 March 2018. 

            Date                                            Total Number of Shares                       Share Capital                Total Number of Votes
                 (nominal value of DKK 0.10 each)        (nominal value in DKK)
     31 August 2018                                         1,712,838,531                            171,283,853.10                  1,712,838,531


For more information, please contact:

Craig Alexander Collard
President & CEO          
Phone: +1 919 591 3090        
Email: cac@veloxis.com


About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

Attachment